Abstract P3-06-10: Immune-related adverse events (irAEs) and pathological complete response (pCR) rates in patients receiving neoadjuvant chemotherapy (CHT) and pembrolizumab (PEM) for early triple-negative breast cancer (eTNBC)
Maximilian Marhold(Medical University of Vienna), Rupert Bartsch(Universitätszahnklinik Wien), Simon Udovica, Kerstin Wimmer(Comprehensive Cancer Center Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Kathrin Strasser‐Weippl(Otto Wagner Hospital), Tim Robinson(University of Bristol), Florian Fitzal
Cited by 2
Related Papers
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|Annals of Oncology|2021|799
Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis
|Nature Communications|2020|694
Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice
|Science|2018|422